Therefore, a hypothesis is put forward that shikonin is a potential PKM2 inhibitor, by inhibiting the glycolysis and exosomal pathways, ultimately inhibiting the proliferation, invasion, migration, and inducing apoptosis of NSCLC cells. This evidence concerns the gene PKM and non-small cell lung carcinoma.